Market-Moving News for December 28th
Portfolio Pulse from ryanfaloona@benzinga.com
Cingulate (CING) received FDA guidance for its ADHD treatment, CTX-1301, and plans to submit an NDA in H1 2025. SEALSQ (LAES) revealed its post-quantum semiconductor technology to secure crypto transactions against quantum threats. Microbot Medical (MBOT) announced the successful completion of its GLP pivotal pre-clinical study under FDA guidelines using a porcine model.
December 28, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cingulate received positive FDA guidance for its ADHD treatment candidate, CTX-1301, and expects to submit an NDA in the first half of 2025.
The positive FDA guidance and expected NDA submission for CTX-1301 is a significant milestone for Cingulate, likely to boost investor confidence and potentially increase the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
SEALSQ disclosed its post-quantum semiconductor technology designed to secure cryptocurrency transactions against quantum computing threats.
The announcement of SEALSQ's post-quantum semiconductor technology addresses a growing concern in the crypto industry about quantum threats, which could attract investor interest and drive up the stock price.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Microbot Medical successfully completed its GLP pivotal pre-clinical study, adhering to FDA guidelines, using a porcine model.
Microbot Medical's announcement of a successful GLP pivotal pre-clinical study is a positive development, indicating progress in its product pipeline which could positively influence its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100